• Explore /
  • Poster
  • / ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.

ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.

Abstract Poster

Authors

Enriqueta Felip

Enriqueta Felip

Vall d´Hebron University Hospital, Barcelona, Spain

Enriqueta Felip , Giuseppe Giaccone , Rafal Dziadziuszko , Fabrice Denis , Teresa Moran , Didier Debieuvre , Manuel Cobo , Domenico Galetta , François Roger Vanel , Giampiero Romano , Anne Madroszyk , Christos Chouaid , Francois-Regis Ferrand , Werner Hilgers , Federico Cappuzzo , Philippe Masson , Nir Peled , Berangere Vasseur , Jordi Remon , Benjamin Besse

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02654587

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS9121)

DOI

10.1200/JCO.2019.37.15_suppl.TPS9121

Abstract #

TPS9121

Poster Bd #

440b

Abstract Disclosures

Similar Posters

First Author: Alexandra Leary

First Author: Benjamin Besse

First Author: Alexandra Leary

First Author: Melissa Lynne Johnson